Literature DB >> 23168019

Isosteric analogs of lenalidomide and pomalidomide: synthesis and biological activity.

Alexander L Ruchelman1, Hon-Wah Man, Weihong Zhang, Roger Chen, Lori Capone, Jian Kang, Anastasia Parton, Laura Corral, Peter H Schafer, Darius Babusis, Mehran F Moghaddam, Yang Tang, Michael A Shirley, George W Muller.   

Abstract

A series of analogs of the immunomodulary drugs lenalidomide (1) and pomalidomide (2), in which the amino group is replaced with various isosteres, was prepared and assayed for immunomodulatory activity and activity against cancer cell lines. The 4-methyl and 4-chloro analogs 4 and 15, respectively, displayed potent inhibition of tumor necrosis factor-α (TNF-α) in LPS-stimulated hPBMC, potent stimulation of IL-2 in a human T cell co-stimulation assay, and anti-proliferative activity against the Namalwa lymphoma cell line. Both of these analogs displayed oral bioavailability in rat.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23168019     DOI: 10.1016/j.bmcl.2012.10.071

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  11 in total

1.  Pomalidomide is nonteratogenic in chicken and zebrafish embryos and nonneurotoxic in vitro.

Authors:  Chris Mahony; Lynda Erskine; Jennifer Niven; Nigel H Greig; William Douglas Figg; Neil Vargesson
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-15       Impact factor: 11.205

2.  Innovations in treatment and response evaluation in multiple myeloma.

Authors:  Ruth Wester; Pieter Sonneveld
Journal:  Haematologica       Date:  2016-05       Impact factor: 9.941

Review 3.  Dissecting fibrosis: therapeutic insights from the small-molecule toolbox.

Authors:  Carmel B Nanthakumar; Richard J D Hatley; Seble Lemma; Jack Gauldie; Richard P Marshall; Simon J F Macdonald
Journal:  Nat Rev Drug Discov       Date:  2015-09-04       Impact factor: 84.694

Review 4.  Pomalidomide: a review of its use in patients with recurrent multiple myeloma.

Authors:  Lesley J Scott
Journal:  Drugs       Date:  2014-04       Impact factor: 9.546

5.  Chemical Degradation of Androgen Receptor (AR) Using Bicalutamide Analog-Thalidomide PROTACs.

Authors:  Ga-Yeong Kim; Chae Won Song; Yo-Sep Yang; Na-Rae Lee; Hyung-Seok Yoo; Seung Hwan Son; Soo Jin Lee; Jong Seon Park; Jong Kil Lee; Kyung-Soo Inn; Nam-Jung Kim
Journal:  Molecules       Date:  2021-04-26       Impact factor: 4.411

6.  Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide.

Authors:  Eric S Fischer; Kerstin Böhm; John R Lydeard; Haidi Yang; Michael B Stadler; Simone Cavadini; Jane Nagel; Fabrizio Serluca; Vincent Acker; Gondichatnahalli M Lingaraju; Ritesh B Tichkule; Michael Schebesta; William C Forrester; Markus Schirle; Ulrich Hassiepen; Johannes Ottl; Marc Hild; Rohan E J Beckwith; J Wade Harper; Jeremy L Jenkins; Nicolas H Thomä
Journal:  Nature       Date:  2014-07-16       Impact factor: 49.962

7.  Macrophage contributes to radiation-induced anti-tumor abscopal effect on transplanted breast cancer by HMGB1/TNF-α signaling factors.

Authors:  Lin Zhu; Songling Hu; Qianping Chen; Haowen Zhang; Jiamei Fu; Yuchuan Zhou; Yang Bai; Yan Pan; Chunlin Shao
Journal:  Int J Biol Sci       Date:  2021-03-01       Impact factor: 6.580

Review 8.  Pomalidomide in the treatment of multiple myeloma: design, development and place in therapy.

Authors:  Rafael Ríos-Tamayo; Agustín Martín-García; Carolina Alarcón-Payer; Dolores Sánchez-Rodríguez; Ana María Del Valle Díaz de la Guardia; Carlos Gustavo García Collado; Alberto Jiménez Morales; Manuel Jurado Chacón; José Cabeza Barrera
Journal:  Drug Des Devel Ther       Date:  2017-08-22       Impact factor: 4.162

9.  Cytotoxicity and pro-apoptosis activity of synthetic 1,3-thiazole incorporated phthalimide derivatives on cancer cells.

Authors:  Omid Tavallaei; Milad Heidarian; Marzieh Marzbany; Alireza Aliabadi
Journal:  Iran J Basic Med Sci       Date:  2021-05       Impact factor: 2.699

10.  Demonstrating In-Cell Target Engagement Using a Pirin Protein Degradation Probe (CCT367766).

Authors:  Nicola E A Chessum; Swee Y Sharp; John J Caldwell; A Elisa Pasqua; Birgit Wilding; Giampiero Colombano; Ian Collins; Bugra Ozer; Meirion Richards; Martin Rowlands; Mark Stubbs; Rosemary Burke; P Craig McAndrew; Paul A Clarke; Paul Workman; Matthew D Cheeseman; Keith Jones
Journal:  J Med Chem       Date:  2018-01-05       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.